142nd APHA Annual Meeting and Exposition

Annual Meeting Recordings are now available for purchase

298247
Pilot evaluation of men who have sex with men's ability to self-administer rapid HIV tests and interpret test results, Atlanta, Georgia, 2013

142nd APHA Annual Meeting and Exposition (November 15 - November 19, 2014): http://www.apha.org/events-and-meetings/annual
Sunday, November 16, 2014

Robin Macgowan, MPH , Division of HIV/AIDS Prevention, NCHHSTP, Centers for Disease Control and Prevention
Pollyanna Chavez, MS, PhD , Division of HIV/AIDS Prevention, NCHHSTP, Centers for Disease Control and Prevention, Atlanta
Arin Freeman, MPH , Division of HIV/AIDS Prevention, NCHHSTP, Centers for Disease Control and Prevention, Atlanta, GA
A.D. McNaghten, PhD, MHSA , Rollins School of Public Health, Emory University, Atlanta, GA
Patrick Sullivan, DVM, PhD , Rollins School of Public Health, Emory University, Atlanta, GA
Akshay Sharma, MBBS, MPH , Rollins School of Public Health, Emory University, Atlanta, GA
Laura Gravens, MS, MPH , Rollins School of Public Health, Emory University, Atlanta, GA
Wayne Johnson, PhD , Centers for Disease Control and Prevention, Atlanta
Andrew Margolis, MPH , Division of HIV/AIDS Prevention, NCHHSTP, Centers for Disease Control and Prevention
Kristina Bowles, MPH , Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA
Background:

Men who have sex with men (MSM) represent approximately 60% of incident HIV cases in the U.S. and may benefit from frequent HIV testing.  As a preliminary step to assessing whether providing MSM with rapid HIV tests increases testing frequency, we evaluated how well a sample of MSM could self-administer rapid HIV tests and interpret test results.   

Methods:

22 MSM were recruited from prior HIV-related studies. Participants were provided written and video instructions and were observed self-administering the OraQuick® In-Home HIV Test (OraQuick) and the SURE CHECK® HIV 1/2 Rapid HIV Test (Sure Check).  Staff verified results. Participants completed online assessments that included interpreting pictures of HIV test results.

Results:

At enrollment 17(77%) reported being HIV-negative, 5(23%) HIV-positive; 19(86%) had post-high school education; and 12(55%) were non-Hispanic Black.  Twenty-one of 22 (95%) correctly conducted the OraQuick test; one spilled the vial contents. All 22 correctly interpreted their own OraQuick results.  Eighteen of 21 (86%) correctly conducted the Sure Check test, 3 had operational errors, and 1(5%) did not conduct the Sure Check test. All 21 correctly interpreted their own Sure Check result (4 HIV+, 14 HIV-, 3 invalid). Percent of pictures correctly interpreted: OraQuick–Positive 98.44%, Negative 100%, Invalid 80.95%;  Sure Check–Positive 94.29%, Negative 92.86%, Invalid 80.95%.

 Conclusions:

Most participants successfully self-administered rapid HIV tests and all correctly interpreted their results.  Interpretation of images depicting invalid results was problematic. Data are needed on the sensitivity and specificity of self-administered rapid HIV tests performed by MSM.   

Learning Areas:

Conduct evaluation related to programs, research, and other areas of practice
Public health or related research
Social and behavioral sciences

Learning Objectives:
Describe how well a sample of MSM were able to self-administer rapid HIV tests and interpret test results.

Keyword(s): HIV Interventions, Men’s Health

Presenting author's disclosure statement:
Organization/institution whose products or services will be discussed: IDE not required by FDA for use of Sure Check HIV rapid test

Qualified on the content I am responsible for because: I serve as an Epidemiologist in the Division of HIV/AIDS Prevention and work on HIV testing projects, including projects related to rapid HIV testing and internet-based projects.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

Back to: 2030.0: Innovations in HIV Testing